Assessment cycle 2023 Q3

Record of documents ratified in the 2023 Q3 assessment cycle.

Consultation on the rubric by which the Institute assesses a supplier dossier. The rubric scores documentary and analytical practice; it does not score product quality…

Consultation on the set of indications the Institute assesses against and the anchor outcome defined for each. The draft fixes one anchor outcome per indication so that…

Sustained elevation of arterial pressure above accepted diagnostic thresholds, considered here as a weight-responsive outcome rather than a primary treatment indication.

An adverse lipoprotein profile, typically raised triglycerides with reduced HDL cholesterol and a raised apolipoprotein B to apolipoprotein A1 ratio.

GLP-1 receptor agonist (acylated, long-acting). Semaglutide is a full agonist at the glucagon-like peptide-1 receptor, a class B G protein-coupled receptor signalling principally through Gαs and…

GLP-1 receptor agonist, oral formulation with absorption enhancer. Receptor pharmacology is identical to subcutaneous semaglutide. The distinguishing pharmacology is absorption: SNAC buffers the gastric…

Non-selective melanocortin receptor agonist (cyclic heptapeptide). Melanotan-II is a potent non-selective melanocortin receptor agonist. MC1R agonism stimulates eumelanin synthesis in melanocytes, producing…

Endogenous decapeptide, gonadotropin-releasing hormone. Gonadorelin stimulates pituitary release of luteinising hormone and follicle-stimulating hormone. Its pharmacology is dominated by a pattern…